| Michael John Maranzano, MD | |
|
10833 Le Conte Ave # 60-054, Los Angeles, CA 90095-3000 | |
| (310) 825-0712 | |
| Not Available |
| Full Name | Michael John Maranzano |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 10833 Le Conte Ave # 60-054, Los Angeles, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114453016 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 170563 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael John Maranzano, MD 10833 Le Conte Ave # 60-054, Los Angeles, CA 90095-3075 Ph: (310) 825-0712 | Michael John Maranzano, MD 10833 Le Conte Ave # 60-054, Los Angeles, CA 90095-3000 Ph: (310) 825-0712 |
News Archive
China PharmaHub Corp., announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz. In addition, PharmaHub contemplates merging with World Wide Relics, Inc. of which it recently purchased a 77% interest.
QHR Technologies Inc. announced today that it has granted an aggregate of 1,000,000 stock options to various directors, employees and consultants of the Company.
As modern medical advances help more children with complex conditions live longer, a new study shows a significant number suffer from complications caused by medical devices that are also necessary for their survival.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
› Verified 4 days ago
Dr. Linda Fong, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6041 Cadillac Ave, Los Angeles, CA 90034 Phone: 323-857-3290 | |
Dr. Robert Peter Gale, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 11693 San Vicente Blvd, Suite 335, Los Angeles, CA 90049 Phone: 310-442-9010 | |
Dr. Tarek Alasil, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 8616 La Tijera Blvd Ste 404, Los Angeles, CA 90045 Phone: 310-673-2020 Fax: 310-469-5290 | |
David Michael Tellalian, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 8635 W 3rd St Ste 465w, Los Angeles, CA 90048 Phone: 310-358-2300 Fax: 310-358-2308 | |
Dr. Jan B King, M.D., M.P.H. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 11833 Wilmington Ave Fl 2, Los Angeles, CA 90059 Phone: 323-568-8701 | |
Dr. Caroline Hwang, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1520 San Pablo St, Suite 1000, Los Angeles, CA 90033 Phone: 323-442-5100 | |
Dr. Jennifer A Fulcher, M.D., PH.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 10833 Le Conte Ave, Chs 37-121, Los Angeles, CA 90095 Phone: 310-825-7225 |